Ponatinib for FLT3-ITD Acute Myelogenous Leukemia
NCT02428543
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
49
Enrollment
OTHER
Sponsor class
Conditions
Acute Myeloid Lukemia
Interventions
DRUG:
Ponatinib and Cytarabine
Sponsor
Versailles Hospital